Bergen, Norway 03.08.21

The European Patent Office (EPO) has as expected decided to grant Lifecare a new
patent for an updated sensor measuring system. The now approved patent expands
Lifecare's protection in time and scope. 

As announced in Lifecare's press release 25.03.21, the EPO by then intended to
grant this patent, about an "interstitial fluid osmotic pressure measuring
device system and method". This protection is now confirmed and ensured until
2038. The new patent represents a fundamental addition to Lifecare's IP and an
important next step utilizing the Sencell technology from research and
development to a broader commercialization. The sensor design described in the
new patent intends to improve signal amplitude, increase the accuracy of
subcutaneous glucose assessment, and to improve sensor longevity and robustness
against environmental interferences. This new sensor version is also suitable
for measurement of other analytes, in addition to glucose.

"As mentioned in March, this European patent will strengthen our position for
correct and continuous monitoring of blood sugar, in people with diabetes. In
addition, a scope of other analytes useful in both a medical and lifestyle
perspective can now be realized. The updated system, which has the size of a
grain of rice, will be used in our upcoming human pilot studies already approved
by German regulatory authorities," says Joacim Holter, CEO Lifecare 

Patent broadens the scope and application of the Sencell technology

"The patent opens the opportunities to expand the use of the Sencell
technology." Says Prof. Andreas Pfützner, Lifecare's Chief Scientific Officer
and one of the patent inventors. "It increases the scope of protection to
include measurement of many parameters in the interstitial fluid, including but
not limited to lactate, fructose, and calcium and many other biomarkers."

This is Lifecare
Lifecare is a Bergen-based technology company developing a miniaturized
implantable long-term sensor for correct and continuous monitoring of blood
sugar in people with diabetes. The company's patented technology also has the
potential for use in various biomarkers. Lifecare AS (Ltd.) is listed on
Euronext Growth (LIFE).

Further information
Joacim Holter, CEO, Lifecare AS,  joacim.holter@lifecare.no, +47 40 05 90 40

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to Section 5-12 the Norwegian Securities Trading Act. This stock exchange
announcement was published by Kine Hereid, Investor Relations at Lifecare AS, on
03.08.2021 at 15:40 CET.